Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6496 to 6510 of 7710 results

  1. Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]

    In development [GID-TAG499] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]

    Discontinued [GID-TA10164]

    Technology appraisal guidance
    Discontinued

  3. Constipation (opioid induced) - lubiprostone [ID646]

    Discontinued [GID-TAG367]

    Technology appraisal guidance
    Discontinued

  4. Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

    Discontinued [GID-HST10007]

    Highly specialised technologies guidance
    Discontinued

  5. Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]

    Discontinued [GID-TAG507]

    Technology appraisal guidance
    Discontinued

  6. Electrochemotherapy for the treatment of malignant melanoma

    Discontinued [GID-IP1041]

    Interventional procedures guidance
    Discontinued

  7. Pacritinib for treating myelofibrosis [ID880]

    Discontinued [GID-TA10133]

    Technology appraisal guidance
    Discontinued

  8. Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]

    In development [GID-TA10598] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis [ID388]

    Discontinued [GID-TAG372]

    Technology appraisal guidance
    Discontinued

  10. Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]

    Discontinued [GID-TA10711]

    Technology appraisal guidance
    Discontinued

  11. Reducing the mortality and morbidity for healthcare associated infections

    Discontinued [GID-NG10059]

    NICE guideline
    Discontinued

  12. Lorcaserin hydrochloride for the treatment of obesity and overweight [ID337]

    Discontinued [GID-TAG420]

    Technology appraisal guidance
    Discontinued

  13. Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897]

    Discontinued [GID-TAG526]

    Technology appraisal guidance
    Discontinued

  14. Masitinib for treating amyotrophic lateral sclerosis [ID967]

    Discontinued [GID-TA10157]

    Technology appraisal guidance
    Discontinued

  15. Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]

    Discontinued [GID-TA10363]

    Technology appraisal guidance
    Discontinued